Asset Details
Do you wish to reserve the book?
Lanadelumab: First Global Approval
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Lanadelumab: First Global Approval
Do you wish to request the book?
Lanadelumab: First Global Approval
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Lanadelumab: First Global Approval
2018
Overview
Shire is developing lanadelumab (Takhzyro™) for the prevention of hereditary angioedema (HAE) attacks. Lanadelumab is a fully human monoclonal antibody that inhibits plasma kallikrein. Mutations in the
SERPING1
gene lead to C1 inhibitor deficiency or dysfunction, resulting in uncontrolled plasma kallikrein activity, which in turn produces excessive bradykinin, a vasodilator thought to cause angioedema symptoms. Subcutaneous administration of lanadelumab significantly reduced HAE attacks versus placebo in patients aged ≥ 12 years with type I or II HAE in a phase III trial. Based on these results, lanadelumab is recently approved in the USA for the prevention of HAE attacks in patients aged ≥ 12 years. It is also preregistered in the EU, Canada, Australia and Switzerland. This article summarizes the milestones in the development of lanadelumab leading to this first approval.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Angioedemas, Hereditary - drug therapy
/ Angioedemas, Hereditary - genetics
/ Antibodies, Monoclonal, Humanized - pharmacokinetics
/ Antibodies, Monoclonal, Humanized - pharmacology
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Asthma
/ Child
/ Clinical Trials, Phase II as Topic
/ Complement C1 Inhibitor Protein - genetics
/ Humans
/ Medicine
/ Mutation
/ Patients
